Update on Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: 3-Year Postmarketing Surveillance Follow-Up in Japan

Masataka Kuwana; Naoko Wakasugi; Tetsuji Hashida; Satoshi Uno; Takafumi Suda

doi:10.3899/jrheum.2024-0379

Update on Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: 3-Year Postmarketing Surveillance Follow-Up in Japan

J Rheumatol. 2024 Sep 15:jrheum.2024-0379. doi: 10.3899/jrheum.2024-0379. Online ahead of print.

Authors

Masataka Kuwana¹, Naoko Wakasugi², Tetsuji Hashida³, Satoshi Uno⁴, Takafumi Suda⁵

Affiliations

¹ Masataka Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo.
² Naoko Wakasugi, MSc, Astellas Pharma Inc., Tokyo.
³ Tetsuji Hashida, MSc, Astellas Pharma Inc., Tokyo.
⁴ Satoshi Uno, MSc, Astellas Pharma Inc., Tokyo.
⁵ Takafumi Suda, MD, Second Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

PMID: 39278651
DOI: 10.3899/jrheum.2024-0379

Abstract

In 2013, tacrolimus was approved in Japan for the treatment of interstitial lung disease (ILD) in patients with polymyositis (PM)/dermatomyositis (DM).¹ Subsequently, Kuwana et al² reported the 2-year interim prospective results of a postmarketing surveillance study, which found that tacrolimus-containing immunosuppressive regimens were well tolerated in patients with PM/DM-associated ILD.².

Publication types

Letter